New menopause drug without hormones approved by FDA. A doctor shares what to know.

The U.S. Food and Drug Administration has approved Lynkuet, a new medication that does not contain hormones to treat hot ...

FDA approves a new drug for hot flashes. Here’s what to know about it.

Elinzanetant belongs to a new class of drugs designed to target what is believed to be a key mechanism responsible for ...

Trump Administration Eases Approval Process for Biosimilar Drugs

The Trump administration is proposing changes to Food and Drug Administration guidelines that would make it less expensive ...

Federal health officials push effort to spur cheaper biotech drugs

Federal regulators are trying to make it easier to develop cheaper alternatives to powerful drugs that many Americans depend ...

Paxton sues Tylenol's maker as Trump administration links the drug to autism

Texas Attorney General Ken Paxton alleged Johnson & Johnson deceptively marketed the drug as safe for pregnant Texans.

FDA to streamline approvals for generic biological drugs in latest move targeting health costs

The US Food and Drug Administration will take steps to streamline the process to develop generic versions of complex ...

Atorvastatin recall may affect hundreds of thousands of patients, and reflects FDA's troubles

If you take cholesterol-lowering drugs called statins, you may have noticed a flurry of news coverage since late October 2025 ...

F.D.A. Moves to Speed Approvals for Cheaper Copycat Drugs

The agency announced moves to cut regulatory obstacles for the makers of biosimilar drugs, which are akin to generics and may ...

Will Donald Trump's fight against high drug costs help India?

The United States has said it will speed up approval for some generic drugs. The development comes weeks after it was ...

Q&A: What new drug is the FDA reviewing to treat Parkinson’s disease?

If approved, it would be the first major new drug treatment for Parkinson’s in half a century. Richard Mailman, a University ...
The Manila Times

Cellectar Biosciences Receives Rare Pediatric Disease Designation from U.S. Food and Drug Administration for Iopofosine I 131 in Relapsed or Refractory Pediatric High-Grade Glioma

CLOVER-2 Phase 1 Clinical Study Evaluating Iopofosine I 131 in Relapsed/Refractory Pediatric High-Grade Glioma Patients Showed Extended Progression Free Survival and Overall Survival ...